Finanzen von iSpecimen Inc (ISPC)ISPCiSpecimen Inc

iSpecimen Inc (ISPC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Specimens – contracts with customers, accounting for 86.2% of total sales, equivalent to $134.41K. Another important revenue stream is Shipping and other. Understanding this composition is critical for investors evaluating how ISPC navigates market cycles within the Software industry.

Evaluating the bottom line, iSpecimen Inc maintains a gross margin of 45.18%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -897.06%, while the net margin is -896.94%. These profitability ratios, combined with a Return on Equity (ROE) of -968.47%, provide a clear picture of how effectively ISPC converts its operational activities into shareholder value.

In the context of the broader market, ISPC competes directly with industry leaders such as KUST and GSUN. With a market capitalization of $2.03M, it holds a significant position in the sector. When comparing efficiency, ISPC's gross margin of 45.18% stands against KUST's -21.87% and GSUN's 2.50%. Such benchmarking helps identify whether iSpecimen Inc is trading at a premium or discount relative to its financial performance.

iSpecimen's financial performance shows significant losses, with a net income of -1,362,811 USD in Q2 2026 and a gross margin of 45.18%. The company has seen a drastic decline in revenue, with Q4 2025 revenue at only 51,761 USD, down from 1,475,507 USD in Q4 2024.